source
- Roche CEO says stance on $1.5B Poseida acquisition unchanged despite dropping one CAR-T programRoche bought Poseida in 2024 for $1.5 billion to secure its off-the-shelf CAR-T platform and strengthen its cell-therapy portfolio. During the third-quarter earnings call, the company said it has…
- Telehealth platforms prescribe GLP-1 drugs off-label for addiction, raising safety concernsTelehealth companies have begun prescribing GLP-1 receptor agonists, originally approved for diabetes and obesity, to patients with alcohol, cocaine, methamphetamine or other substance use disorder…